Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide that seriously threatens human health. Chronic infection of hepatitis virus B, C and D is closely related to the occurrence of HCC, about 80% HCC cases are caused by chronic viral hepatitis. Effective antiviral therapy can control liver inflammation, reduce the occurrence of HCC and reduce the recurrence of HCC after surgery treatment. In addition, during chemotherapy such as transarterial chemoembolization (TACE) or hepatic artery infusion chemotherapy (HAIC), targeted therapy and immunotherapy for HCC, antiviral therapy is also needed to prevent hepatitis virus reactivation. Therefore, antiviral therapy plays an important role in the prevention and treatment of HCC.